Journal Mobile Options
Table of Contents
Vol. 14, No. 5, 1976
Issue release date: 1976
Section title: Paper
Eur Neurol 1976;14:321–327
(DOI:10.1159/000114756)

Mortality among Parkinson Patients Treated with L-Dopa Combined with a Decarboxylase Inhibitor

Zumstein H. · Siegfried J.
Department of Neurological Surgery, Kantonsspital, University of Zurich, Zurich

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Received: 7/28/1975
Accepted: 11/10/1975
Published online: 1/25/2008

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: http://www.karger.com/ENE

Abstract

Since L-dopa in combination with a decarboxylase inhibitor is currently the most effective therapy available for treatment of Parkinson’s disease, the authors compare the actual causes of death in a large series of treated Parkinson patients with a normal population and with previous studies. This investigation shows that the mortality of correctly treated Parkinson patients lies within the range of the expected mortality of a group of a normal population comparable in age and sex. The risk of death for a Parkinson patient is therefore no longer higher than for the normal population.


  

Author Contacts

Prof. Dr. J. Siegfried, Kantonsspital Zürich, Neurochirurgische Universitätsklinik, Ramistrasse 100, CH-8006 Zürich (Switzerland)

  

Article Information

Received: July 28, 1975
accepted: November 10, 1975
Published online: January 25, 2008
Number of Print Pages : 7

  

Publication Details

European Neurology

Vol. 14, No. 5, Year 1976 (Cover Date: 1976)

Journal Editor: Bogousslavsky, J. (Montreux)
ISSN: 0014–3022 (Print), eISSN: 1421–9913 (Online)

For additional information: http://www.karger.com/ENE


Article / Publication Details

First-Page Preview
Abstract of Paper

Received: 7/28/1975
Accepted: 11/10/1975
Published online: 1/25/2008

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: http://www.karger.com/ENE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.